FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 482 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR Diving into our role in 50 top cancer drugs February 9, 2022 Trialling a new way to boost CAR T-cell therapy June 23, 2021 A New FDA Approval Furthers the Role of Genomics in Cancer... July 8, 2020 2025 ESMO Society Award recipients announced August 5, 2025 Load more HOT NEWS Colon capsule endoscopy – reshaping bowel cancer diagnosis Median Survival Times for Two Forms of Advanced Breast Cancer Have... Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney
